News | June 15, 2022
Dr. Reddy's Lab launches sorafenib tablets in US
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The product will be launched by NATCO's commercial partner Viatris.
Subscribe To Our Newsletter & Stay Updated
